Navigation Links
Bend Research Clients May Now Reference Key Safety Document for Important Solubility Excipient
Date:12/15/2009

BEND, Oregon, December 15 /PRNewswire/ -- Bend Research Inc. announced today that its clients may now reference a key safety file for HPMCAS, an excipient used in technologies developed by the firm to enhance the oral bioavailability of clients' low-solubility drugs.

Bend Research clients may now reference a Type V Drug Master File (DMF) for HPMCAS for regulatory filings with the FDA, Bend Research officials said.

"We're excited about this new development and know it will assist our clients in accelerating the regulatory process for new therapeutic products," Bend Research CEO Rod Ray explained.

HPMCAS-hypromellose acetate succinate-is a polymeric excipient with a demonstrated safety record for use in humans. The polymer is used in Bend Research drug-delivery technologies such as spray-dried dispersions (SDDs), which have successfully enhanced the oral bioavailability for scores of low-solubility drugs.

The Type V DMF for HPMCAS was filed with the FDA in 2005 by Pfizer Inc., the sponsor of Bend Research's work investigating the use of HPMCAS to improve drug solubility. This Type V DMF contains supplemental nonclinical safety data-including absorption, distribution, metabolism, and excretion (ADME) data-to support chronic and high-dosage use of HPMCAS as an excipient for human oral delivery.

The Type V DMF supplements the DMF filed by Shin-Etsu Chemical Co. and provides additional data to support the use of HPMCAS in SDDs for improving oral drug bioavailability.

Bend Research clients may obtain a letter of authorization that allows the FDA to reference the Type V DMF for regulatory reviews such as Investigational New Drug (IND), New Drug Application (NDA), or Abbreviated New Drug Application (ANDA) reviews. (Contact: Dana Settell, 541-382-4100)

"The availability of the Type V DMF for HPMCAS adds significant value to the formulation work we perform for our clients," Ray said. "It provides additional safety data our clients can reference during the FDA approval process for the new therapeutics we develop with them."

About Bend Research Inc.

Bend Research has more than 30 years of experience in helping clients solve their most difficult scientific and technical problems. The firm has a long, established track record of matching the right technologies with the customers' needs to provide a rapid, straightforward solution. As CEO Rod Ray states, "Our goal at Bend Research is to be the leading drug formulation problem-solving company in the world in terms of the best performance, speed, and cost-which all boils down to client value."

Bend Research provides formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facility, and advances promising drug candidates from conception through to commercialization.

The company's flexible, client-focused business model and collaborative approach to working with its customers result in long-term partnerships focused on value creation.

Bend Research has more than 140 employees based in three state-of-the-art facilities in Bend, Oregon, USA.

    Contact:

    Dana Settell
    Bend Research Inc.
    64550 Research Road
    Bend, OR 97701
    Phone: +1-541-382-4100
    Fax: +1-541-382-2713
    E-mail: settell@bendres.com


SOURCE Bend Research Inc.


'/>"/>
SOURCE Bend Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
2. US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
3. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
4. Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation
5. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
6. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
7. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
8. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
9. New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults
10. Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker
11. Alzheimers Research May Lead to Preventing the Debilitating Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):